Code |
Compound |
|
4171 |
Fibronectin Active Fragment (RGDS) |
|
4171-v |
Fibronectin Active Fragment (RGDS) |
|
4189 |
Fibronectin Active Fragment (GRGDS) |
|
4189-v |
Fibronectin Active Fragment (GRGDS) |
|
4304 |
cyclo(Arg-Gly-Asp-D-Phe-Val) |
Angiogenesis Inhibitor |
4304-v |
cyclo(Arg-Gly-Asp-D-Phe-Val) |
Angiogenesis Inhibitor |
4532 |
Cyclo(Arg-Gly-Asp-D-Phe-Lys) |
αvß3 Integrin Binding RGD Peptide RGD Tumor Targeting Peptide(Requires Further Derivatization Before Use) |
4532-v |
Cyclo(Arg-Gly-Asp-D-Phe-Lys) |
αvß3 Integrin Binding RGD Peptide RGD Tumor Targeting Peptide(Requires Further Derivatization Before Use) |
CAN-3505-PI |
H-[Lys-Leu-Ala-Lys-Leu-Ala-Lys]2-Gly-Phe-Leu-Gly-(Cys-Gln-Thr-Pro-Tyr-Tyr-Met-Asn-Thr-Cys)-OH |
Cell Penetrating Peptide (CPP). Targets EGFR, Binding to a Specific Protein in Carcinoma Cells, and Induces Apoptosis. |
ECT-3760-PI |
Echistatin |
αVß3 Integrin Antagonist |
FAP-3758-PI |
Fibronectin Adhesion-Promoting Peptide |
|
PCA-3618-PI |
Cyclo(Arg-Ala-Asp-D-Phe-Val) |
Negative Control for 4304 |
3438-v |
Glu[Cyclo(Arg-Gly-Asp-D-Phe-Lys)]2 |
αvß3 Integrin Binding RGD Peptide; RGD Tumor Targeting Peptide (Requires further derivatization before use) |
PCI-3662-PI |
Cyclo(Arg-Gly-Asp-D-Tyr-Lys) |
αvß3 Integrin Binding RGD Peptide RGD Tumor Targeting and Tumor Imaging Peptide (Requires Further Derivatization Before Use) |
PCI-3686-PI |
Cyclo(Arg-Gly-Asp-D-Phe-Cys) |
RGD Tumor Targeting Peptide (linker additions via Cys) (May Require Further Derivatization Before Use) |
PCI-3687-PI |
Cyclo(Arg-Gly-Asp-D-Phe-Glu) |
RGD Peptide for Radiolabeling and Imaging (Requires Further Derivatization Before Use) |
PCI-3688-PI |
Cyclo(Arg-Gly-Asp-D-Tyr-Glu) |
RGD Peptide for Radiolabeling (Requires further derivatization before use) |
PCI-3696-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG-PEG)] |
RGD Peptide Equipped with PEG Spacers for More Efficient Binding to Lipid Surfaces(Requires Further Derivatization Before Use) |
PCI-3697-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(Biotin-PEG-PEG)] |
RGD Peptide Equipped with a Biotin Reporting Tag and PEG Spacers for More Efficient Binding to Lipid Surfaces (Requires Further Derivatization Before Use) |
PCI-3699-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(Ac-SCH2CO)] |
RGD Peptide Equipped with Thioacetyl Group for Linking to Liposomes (May Require Further Derivatization and Deprotection Before Use) |
PCI-3790-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(dPEG®4)] |
RGD Tumor Targeting (and With Radiolabeling, A Tumor Imaging Peptide) |
PCI-3808-PI |
Cyclo[Arg-Ala-Asp-D-Phe-Lys(Biotin-PEG-PEG)] |
Negative Control Peptide for PCI-3697-PI |
PCI-3823-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG-PEG-Cys)] |
|
PCI-3861-PI |
Cyclo[Arg-Gly-Asp-D-Tyr-Lys(Cys-AEEA-DOTA)] |
RGD Peptide Functionalized with a Radiometal Chelator, DOTA (1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid); Potentially Useful for Tumor Targeting and Imaging. |
PCI-3883-PI |
Cyclo(Arg-Ala-Asp-D-Phe-Lys) |
Negative Control RGD Peptide for 4532 |
PCI-3894-PI |
Cyclo(Arg-Ala-Asp-D-Tyr-Lys) |
Control Peptide of cyclo (Arg-Gly-Asp-D-Tyr-Lys) (PCI-3662-PI) |
PCI-3895-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(Biotin)] |
RGD Peptide Equipped with a Biotin Reporting Tag |
PCI-3898-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(H-Ser)] |
αvß3 Integrin Binding RGD Peptide; RGD Tumor Targeting Peptide (Requires further derivatization before use) |
PCI-3899-PI |
H-Glu[Cyclo(Arg-Gly-Asp-D-Tyr-Lys)]2 |
Tumor Targeting and Tumor Imaging Peptide (Requires Further Derivatization Before Use) |
PCI-3903-PI |
DOTA-Glu-[Cyclo(Arg-Gly-Asp-D-Phe-Lys)]2 |
αvß3 Integrin Binding RGD Peptide RGD Tumor Targeting Peptide for Radiolabelling (Requires further derivatization before use) |
PCI-3904-PI |
H-Glu[Cyclo(Arg-Gly-Asp-D-Phe-Lys)]2 |
RGD Tumor Targeting and Tumor Imaging Peptide (Requires further derivatization before use) |
PCI-3909-PI |
H-Gly-Arg-Gly-Asp-Asn-Pro-OH |
RGD peptide and Inhibitor of Cell Adhesion to Fibronectin |
PCI-3910-PI |
H-Gly-Arg-Ala-Asp-Ser-Pro-OH |
Negative Control for Fibronectin Inhibitors |
PCI-3912-PI |
Cyclo(Arg-Gly-Asp-D-Tyr-Cys) |
|
PCI-3917-PI |
Cyclo(Arg-Ala-Asp-D-Tyr-Cys) |
|
PCI-3919-PI |
Cyclo(Arg-Gly-Asp-D-Phe-Lys) |
RGD Tumor Targeting Peptide (Requires further derivatization before use) |
PCI-3929-PI |
H-Arg-Gly-Asp-Ser-Lys-OH |
RGD Tumor-Targeting Peptide |
PCI-3930-PI |
H-Arg-Ala-Asp-Ser-Lys-OH |
Negative Control for PLI-3929-PI |
PCI-3953-PI |
Cyclo(Arg-Gly-Glu-D-Phe-Lys) |
|
PCI-3954-PI |
Cyclo[Arg-Ala-Asp-D-Phe-Lys(PEG-PEG)] |
Negative Control Peptide for PCI-3696-PI |
PCI-3959-PI |
Cyclo[Arg-Ala-Asp-D-Phe-Lys(Ac-SCH2CO)] |
Control for PCI-3699-PI |
PCI-3960-PI |
Cyclo(Arg-Ala-Asp-D-Phe-Cys) |
Negative Control Peptide for PCI-3686-PI |
PCI-3963-PI |
H-Pro-His-Ser-Arg-Asn-OH |
|
PCI-3964-PI |
H-Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-OH |
CD36 Binding Peptide |
PCI-3965-PI |
H-Gly-Gly-Gly-Gly-Arg-Gly-Asp-Ser-Pro-OH |
|
PCI-3975-PI |
H-Glu{Glu[Cyclo(Arg-Gly-Asp-D-Phe-Lys)]2}2 |
Tetrameric RGD Peptide |
PCI-3977-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG-COCH2CH2SH)] |
|
PCI-3979-PI |
H-Glu[Cyclo(Arg-Ala-Asp-D-Phe-Lys)]2 |
Negative Control Peptide for PCI-3651-PI |
PFA-3907-PI |
H-Gly-Arg-Gly-Glu-Ser-OH |
Negative Control for 4189-v |
PFA-3924-PI |
Ac-Gly-D-Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-(Gly)4-Ser-D-Arg-(Leu)6-D-Arg-NH2 |
Hydrophobic RGD Fibronectin Peptide |
RGD-3000-PI |
Cyclo[Arg-Gly-Asp-D-Tyr-Lys(PEG)] |
|
RGD-3005-PI |
Cyclo[Arg-Ala-Asp-D-Tyr-Lys(PEG)] |
Control peptide for RGD-3000-PI |
RGD-3035-PI |
Ac-cyclo [Pen-Tyr(Me)-Ala-Arg-Gly-Asp-Asn-Tic-Cys]-NH2 |
Cell Penetrating Peptide That Targets EGFR, Binds to a Specific Protein in Carcinoma Cells, and Induces Apoptosis |
RGD-3506-PI |
H-Gly-Arg-Gly-Asp-Ser-Pro-Cys-OH |
Thiolated Cell Adhesion Peptide |
RGD-3736-PI |
Galactosyl-Cyclo(Arg-Gly-Asp-D-Phe-Lys) |
Glycosylated RGD for Radiolabelling |
RGD-3749-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)] |
Clickable RGD for Dendrimer Constructs |
RGD-3750-PI |
H-dPEG®4-Glu[dPEG®4(Cyclo(Arg-Gly-Asp-d-Phe-Lys))]2 |
For In Vitro Assays of Integrin αvß3/αvß5 Expression in Tumor Tissues |
RGD-3759-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG-PEG-Azide)] |
Clickable RGD for Dendrimer Constructs |
RGD-3761-PI |
H-[Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys]-NH2 |
RGD Tumor Targeting Peptide |
RGD-3762-PI |
H-[Cys-Arg-Gly-Asp-Arg-Gly-Pro-Asp-Cys]-NH2 |
RGD Tumor Targeting Peptide |
RGD-3766-PI |
H-AEEEA-Glu[Cyclo(Arg-Gly-Asp-D-Tyr-Lys)]2 |
Bicyclic RGD Peptide for Imaging |
RGD-3782-PI |
Galacto-RGD2 |
Ddimer |
3437-v |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(Cys)] |
RGD Peptide for Radiolabeling and Imaging |
RGD-3795-PI |
Cyclo[Arg-Gly-Asp-D-Phe-Lys(Mal)] |
RGD Peptide With 3-Maleimidopropionic Acid Functional Group |
RGD-3842-PI |
Cyclo[Arg-Ala-Asp-D-Phe-Lys(Azide)] |
Negative Control Peptide for RGD-3749-PI |
RGD-3879-PI |
N3-PEG-PEG3-Glu[Cyclo(Arg-Gly-Asp-D-Tyr-Lys)]2 |
Bicyclic RGD peptide Optimized for Click Chemistry |
RGD-3993-PI |
Mal-PEG3-Glu[Cyclo(Arg-Gly-Asp-D-Tyr-Lys)]2 |
Dimeric RGD peptide for click chemistry |